arrow
I

Iwona Danielewicz

bcu
H指数:8
被引数:639

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

沙西妥昔单抗 govitecan 治疗的 mTNBC 中的一级 G-CSF 预防:来自跨国 CEBCC-102 研究队列的真实世界证据

2026-09-280
OAAI
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者的联合阳性评分状态: 中欧队列中的相关临床特征和测试模式

2026-02-020
PRE
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
2026-01-240
OA
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

sacituzumab govitecan在预先治疗的三阴性乳腺癌和脑转移患者中的真实结果: 来自CEBCC-102研究的数据

2026-01-140
PRE
Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
2026-01-120
OAAI
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Sacituzumab govitecan在转移性化生性三阴性乳腺癌患者中的疗效与安全性:一项来自CEBCC-102研究的跨国回顾性病例系列研究

2025-12-090
OAAI
REAL-WORLD OUTCOMES WITH PALBOCICLIB, RIBOCICLIB, AND ABEMACICLIB PLUS ENDOCRINE THERAPY IN HR+/HER2− ADVANCED BREAST CANCER: A MULTICENTER RETROSPECTIVE STUDY

真实世界研究中,PALBOCICLIB、RIBOCICLIB和ABEMACICLIB联合内分泌疗法在HR+/HER2−晚期乳腺癌中的疗效:一项多中心回顾性研究

2025-11-240
OAAI
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
2023-12-204
OAAI
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
2023-11-286
OAAI
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
2020-09-0145
OAAI